AMGNNEUTRAL

Gross Margin

68.2%

Higher than 44% of Healthcare sector peers

Updated 1878h ago

Sector Performance

44th percentile

AMGN

68.2%

Sector Median

69.8%

Sector Avg

-24.1%

📊

Deep Analysis

Amgen’s gross margin of 68.2% means that for every dollar of revenue, the company keeps about 68 cents after accounting for the direct costs of producing its drugs.

This figure sits just below the healthcare sector median of 69.4%, placing Amgen in the 45th percentile among its sector peers—essentially middle-of-the-pack. There is no trend data available: the year-over-year change, quarter-over-quarter change, and direction over the last eight quarters are all reported as N/A, so it is impossible to say whether margins are improving or deteriorating. The combination of a gross margin near the sector median with no observable trend implies a neutral level of risk—there is no clear advantage or warning from this metric alone. This metric supports the overall NEUTRAL verdict, as it neither strengthens nor weakens the case for a bullish or bearish outlook on the stock.

Frequently Asked Questions

What does the Gross Margin tell investors about AMGN?

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

How is the Gross Margin calculated?

Gross Margin is calculated as: Gross Profit / Revenue.

How does AMGN's Gross Margin compare to its sector?

AMGN's Gross Margin of 68.2% compares to a Healthcare sector median of 69.8%, placing it in the 44th percentile.

Who are AMGN's closest peers by Gross Margin?

The closest Healthcare peers by Gross Margin include: BMY (70.2%), TDOC (67.8%), TECH (66.9%), RMD (62.2%), BAYRY (61.0%).

The Formula

Gross Profit / Revenue

Why It Matters

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.